These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 18332109

  • 1. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
    Salat D, Liefke R, Wiedenmann J, Borggrefe T, Oswald F.
    Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
    [Abstract] [Full Text] [Related]

  • 2. RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence Notch target genes.
    Oswald F, Winkler M, Cao Y, Astrahantseff K, Bourteele S, Knöchel W, Borggrefe T.
    Mol Cell Biol; 2005 Dec; 25(23):10379-90. PubMed ID: 16287852
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.
    Guo C, Hu Q, Yan C, Zhang J.
    Mol Cell Biol; 2009 May; 29(10):2644-57. PubMed ID: 19289505
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B, Serve H, Berdel WE, Agrawal S, Linggi B, Büchner T, Hiebert SW, Müller-Tidow C.
    Proc Natl Acad Sci U S A; 2003 Jul 08; 100(14):8448-53. PubMed ID: 12819347
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
    Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM.
    Proc Natl Acad Sci U S A; 1998 Sep 01; 95(18):10860-5. PubMed ID: 9724795
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. E protein silencing by the leukemogenic AML1-ETO fusion protein.
    Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG.
    Science; 2004 Aug 27; 305(5688):1286-9. PubMed ID: 15333839
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JHA, Rawat VPS, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C.
    Cell Rep; 2016 Jul 12; 16(2):498-507. PubMed ID: 27346355
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD.
    Proc Natl Acad Sci U S A; 1996 Nov 26; 93(24):14059-64. PubMed ID: 8943060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.